STAT Plus: Wegovy and Zepbound get primetime treatment
Today's biotech news includes a pioneering new gene therapy for MLD, the plight of WuXi AppTec in the U.S., and more.
Read The StorySTAT has a team of reporters covering health care politics and policy out of Washington, D.C., bringing you the latest from the halls of Capitol Hill, from the White House podium, and from inside key agencies like the FDA, HHS, CDC, and NIH.
STAT offers breaking news, investigations, and features about the ways policymakers’ decisions affect the pharma, biotech, hospitals, insurance, health tech and medical device industries — and how those industries, in turn, are working hard and spending big to affect policy, too.
The team is covering everything from drug pricing to Medicare regulation. We’re tracking major politicians’ health- and science-focused campaign promises and key Supreme Court decisions that affect the U.S. health care landscape.
To get the latest health care politics and policy news delivered to your inbox, sign up for our free, twice-weekly D.C. Diagnosis newsletter. And subscribe to STAT+ for inside intelligence on all these issues and more.
Today's biotech news includes a pioneering new gene therapy for MLD, the plight of WuXi AppTec in the U.S., and more.
Read The Storyadvertisement